GSK has agreed to license worldwide exclusive rights to develop, manufacture and commercialise its investigational liver disease drug linerixibat to Alfasigma. GSK will receive $300 million upfront plus potential additional payments tied to regulatory approvals and sales milestones, along with tiered double-digit royalties on global net sales, according to GSK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.